Human Oncology & Pathogenesis Program
The Jorge Reis-Filho Lab
The focus of my laboratory is on the identification of the drivers of special histological types of breast cancer, rare forms of the disease that together account for up to 25 percent of all invasive breast cancers, using a combination of massively parallel sequencing and functional genomics approaches. These rare forms of breast cancer have been shown to be less transcriptomically and genomically heterogeneous than the common type of the disease, the so-called invasive ductal carcinomas.
Dhomen N, Reis-Filho JS, da Rocha Dias S, Hayward R, Savage K, Delmas V, Larue L, Pritchard C, Marais R. Oncogenic Braf induces melanocyte senescence and melanoma in mice. Cancer Cell. 2009 Apr 7;15(4):294-303. doi: 10.1016/j.ccr.2009.02.022.
Weigelt B, Mackay A, A’hern R, Natrajan R, Tan DS, Dowsett M, Ashworth A, Reis-Filho JS. Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol. 2010 Apr;11(4):339-49. doi: 10.1016/S1470-2045(10)70008-5. Epub 2010 Feb 22.
Mackay A, Weigelt B, Grigoriadis A, Kreike B, Natrajan R, A’Hern R, Tan DS, Dowsett M, Ashworth A, Reis-Filho JS. Microarray-based class discovery for molecular classification of breast cancer: analysis of interobserver agreement. J Natl Cancer Inst. 2011 Apr 20;103(8):662-73. doi: 10.1093/jnci/djr071. Epub 2011 Mar 18.
Kohsaka S, Shukla N, Ameur N, Ito T, Ng CK, Wang L, Lim D, Marchetti A, Viale A, Pirun M, Socci ND, Qin LX, Sciot R, Bridge J, Singer S, Meyers P, Wexler LH, Barr FG, Dogan S, Fletcher JA, Reis-Filho JS, Ladanyi M. A recurrent neomorphic mutation in MYOD1 defines a clinically aggressive subset of embryonal rhabdomyosarcoma associated with PI3K-AKT pathway mutations. Nat Genet. 2014 Jun;46(6):595-600. doi: 10.1038/ng.2969. Epub 2014 May 4.
Weinreb I, Piscuoglio S, Martelotto LG, Waggott D, Ng CK, Perez-Ordonez B, Harding NJ, Alfaro J, Chu KC, Viale A, Fusco N, da Cruz Paula A, Marchio C, Sakr RA, Lim R, Thompson LD, Chiosea SI, Seethala RR, Skalova A, Stelow EB, Fonseca I, Assaad A, How C, Wang J, de Borja R, Chan-Seng-Yue M, Howlett CJ, Nichols AC, Wen YH, Katabi N, Buchner N, Mullen L, Kislinger T, Wouters BG, Liu FF, Norton L, McPherson JD, Rubin BP, Clarke BA, Weigelt B, Boutros PC, Reis-Filho JS. Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. Nat Genet. 2014 Sep 21. doi: 10.1038/ng.3096.
Jorge S. Reis-Filho, MD, PhD
- Physician-scientist Jorge Reis-Filho focuses on the development of a predictive molecular classification for rare types of breast cancer and characterization of intratumor genetic heterogeneity in breast cancers.
- Future Leaders in Cancer Research Prize, Cancer Research UK (2010)
- Ramzi Cotran Young Investigator Award, United States and Canadian Academy of Pathology (2010)
- Young Cancer Researcher Award -- Highly Commended, European Association for Cancer Research (2008)
- CL Oakley Lectureship, Pathological Society of Great Britain and Ireland (2007)
- Translational Research Award, British Association for Cancer Research (2007)
- Sir Anthony Driver Award, Breakthrough Breast Cancer, Institute of Cancer Research (2005)
Postdoctoral Research Fellow
We are currently seeking a postdoctoral research fellow to join our team of bioinformaticians, molecular biologists, and pathology fellows addressing the identification of driver mutations in rare cancer types and the challenges posed by intra-tumor genetic heterogeneity in cancers.
Get in Touch
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Jorge S. Reis-Filho discloses the following relationships and financial interests:
Ownership / Equity Interests; Provision of Services
Provision of Services
Provision of Services
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.